- Home
- ACRV vs VLT Comparison
ACRV vs VLT Comparison
Compare ACRV & VLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRV | VLT |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 71.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRV | VLT |
|---|---|---|
| Price | $2.08 | $11.12 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 22.9K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $805.34 | N/A |
| P/E Ratio | ★ N/A | $16.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $9.29 |
| 52 Week High | $8.00 | $10.93 |
Technical Indicators
Market Signals| Indicator | ACRV | VLT |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 43.62 |
| Support Level | $1.57 | $11.01 |
| Resistance Level | $2.19 | $11.21 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 25.13 | 36.67 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About VLT Invesco High Income Trust II
Invesco High Income Trust II is a diversified, closed-end management investment company. Its investment objective is to provide high current income, while seeking to preserve shareholders' capital through investment in a professionally managed, diversified portfolio of high-income producing fixed-income securities.